The latest oncology news listed by date, covering all clinical focus areas, tumour types and more
FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
On September 25, 2025, the Food and Drug Administration approved imlunestrant, an oestrogen receptor antagonist,…